How Analysts Feel About Novabay Pharmaceuticals Inc (NYSEAMERICAN:NBY) After Increase in Sellers?

March 22, 2018 - By reb123z

 How Analysts Feel About Novabay Pharmaceuticals Inc (NYSEAMERICAN:NBY) After Increase in Sellers?

The stock of Novabay Pharmaceuticals Inc (NYSEAMERICAN:NBY) registered an increase of 11.29% in short interest. NBY’s total short interest was 134,100 shares in March as published by FINRA. Its up 11.29% from 120,500 shares, reported previously. With 12,500 shares average volume, it will take short sellers 11 days to cover their NBY’s short positions. The short interest to Novabay Pharmaceuticals Inc’s float is 2.61%.

The stock increased 2.78% or $0.1 during the last trading session, reaching $3.7. About 6,092 shares traded. NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has risen 7.90% since March 22, 2017 and is uptrending. It has underperformed by 8.80% the S&P500.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States. The company has market cap of $56.92 million. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. It currently has negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.

More notable recent NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) news were published by: which released: “NovaBay Pharmaceuticals Announces CFO Transition” on July 10, 2017, also with their article: “NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 …” published on December 22, 2017, published: “NovaBay Pharmaceuticals Q4 Earnings Outlook” on March 20, 2018. More interesting news about NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) were released by: and their article: “NovaBay Pharmaceuticals Names Lewis J. Stuart Chief Commercial Officer” published on December 06, 2017 as well as‘s news article titled: “NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued …” with publication date: December 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.